GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Total Receivables

Biomarin Pharmaceutical (FRA:BM8) Total Receivables : €631 Mil (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Total Receivables?

Biomarin Pharmaceutical's Total Receivables for the quarter that ended in Dec. 2024 was €631 Mil.


Biomarin Pharmaceutical Total Receivables Historical Data

The historical data trend for Biomarin Pharmaceutical's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Total Receivables Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 368.55 330.46 435.48 581.11 630.81

Biomarin Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 581.11 586.19 642.16 700.57 630.81

Biomarin Pharmaceutical Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Biomarin Pharmaceutical Total Receivables Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Biomarin Pharmaceutical Headlines

No Headlines